

oligonucleotide was purchased from J-Bio 21 Corporation. BODIPY FL was attached to the 5'-end via an aminohexylphosphate linker with a six-carbon spacer. Unlabeled oligonucleotides were purchased from Japan Bio Services Co., Ltd. The PET NS3 helicase assay was carried out in 22  $\mu$ L of 25 mM MOPS-NaOH (pH 6.5) containing 3 mM MgCl<sub>2</sub>, 2 mM dithiothreitol (DTT), 4 U RNasin, 50 nM of the double-strand RNA described above, 100 nM DNA capture strand, 5 mM ATP, and the extract (25  $\mu$ g/mL) and 240 nM HCV NS3 helicase. The reaction was started by the addition of HCV NS3 helicase. The reaction mixture was incubated at 37 °C for 30 min. The fluorescence intensity was recorded every 5 s until 5 min post-reaction, and then every 30 s between 5 and 30 min post-reaction by using a LightCycler 1.5 (Roche Diagnostics, Tokyo, Japan). The initial reaction velocity was calculated and represented as NS3 helicase activity.

### 3.3. ATPase Assay

NS3 ATPase activity was determined by the method of Gallinari *et al.* [39] with slight modifications. The reaction was carried out at 37 °C for 10 min in 10  $\mu$ L of the reaction mixture containing 25 mM MOPS-NaOH (pH 7.0), 1 mM DTT, 5 mM MgCl<sub>2</sub>, 5 mM CaCl<sub>2</sub>, 1 mM [ $\gamma$ -<sup>32</sup>P] ATP (Muromachi, Tokyo, Japan), 300 nM NS3, and 0.1  $\mu$ g poly (U) per microliter and an indicated concentration of SG1-23-1, and then was terminated by the addition of 15 microliters of 10 mM EDTA. Two microliters of the reaction mixture were spotted onto a polyethyleneimine cellulose sheet (Merck, Darmstadt, Germany) and then developed in 0.75 M LiCl/1 M formic acid solution at room temperature for 20 min. The sheet was air-dried completely and then exposed to an image plate. Radioactive bands were visualized with an Image Reader FLA-9000 and quantified by Multi Gauge V 3.11 software (version 3.11; Fujifilm: Tokyo, Japan, 2008).

### 3.4. RNA Helicase Assay

NS3 RNA helicase assay was carried out by the method of Gallinari *et al.* [39] with slight modifications. The substrate for annealing two complementary RNA oligonucleotides, 5'-AGAGAGAGAGGUUGAGAGAGAGAGAGUUUGAGAGAGAGAG-3' (40-mer, template strand) and 5'-CAAACUCUCUCUCUCAACAAAAA-3' (26-mer, release strand) was purchased from Shanghai GenePharma Co., Ltd. The release strand was labeled at the 5'-end with [ $\gamma$ -<sup>32</sup>P] ATP (Muromachi, Tokyo, Japan) using the T4 polynucleotide kinase (Toyobo, Osaka, Japan) at 37 °C for 60 min and then purified by phenol chloroform extraction. The template and the labeled release strands were annealed at a molar ratio of 3:1 (template: release), denatured at 80 °C for 5 min, and slowly renatured at 23 °C for 30 min in an annealing buffer consisting of 20 mM Tris-HCl (pH 8), 0.5 M NaCl, and 1 mM EDTA. The partial duplex RNA substrate was purified on a G-50 micro column (GE Healthcare, Uppsala, Sweden) and stored at -20 °C in H<sub>2</sub>O containing 0.25 U of RNasin Plus (Promega, Madison, WI, USA) per microliter.

SG1-23-1 extract was added at various concentrations to a helicase reaction mixture consisting of 25 mM MOPS-NaOH (pH 7.0), 2.5 mM DTT, 2.5 U of RNasin Plus (Promega), 100  $\mu$ g of BSA per milliliter, and 3 mM MgCl<sub>2</sub>. The mixture was supplemented with 300 nM NS3 protein and 5 fM <sup>32</sup>P-labeled partial duplex RNA substrate. It was then preincubated at 23 °C for 15 min. After adding ATP at a final concentration of 5 mM, the reaction mixture (20  $\mu$ L) was incubated at 37 °C for 30 min

and stopped by adding 5  $\mu$ L helicase termination buffer consisting of 0.1 M Tris-HCl (pH 7.5), 20 mM EDTA, 0.5% SDS, 0.1% Nonidet P-40, 0.1% bromophenol blue, 0.1% xylene cyanol, and 25% glycerol. The terminated reaction mixture was subjected to native TBE 10% polyacrylamide gel electrophoresis. The radioactive RNAs in the gel were visualized with an Image Reader FLA-9000 (Fujifilm) and quantified by Multi Gauge V 3.11 software.

### 3.5. RNA Binding Assay

RNA binding to NS3 helicase was analyzed by gel mobility shift assay [40]. First, let-7 single-strand RNA (5'-UGAGGUAGUAGGUUGUAUAGU-3') was incubated with [ $\gamma$ - $^{32}$ P] ATP (Muromachi, Tokyo, Japan) and T4 polynucleotide kinase (Toyobo) at 37 °C for 60 min for labeling at the 5'-end of the single-strand RNA. The reaction mixture was subjected to phenol chloroform extraction for purification of labeled RNA. The reaction was carried out at room temperature for 15 min in 20  $\mu$ L of the mixture consisting of 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM MgCl<sub>2</sub>, 1 mM DTT, 1 unit of RNasin Plus (Promega) per microliter, 300 nM NS3, 5 fmol let-7-labeled ssRNA, and an indicated concentration of SG1-23-1. The reaction was stopped by adding an equal volume of dye solution consisting of 0.025% bromophenol blue, 10% glycerol, and 0.5 $\times$  Tris/borate/EDTA (TBE). The resulting mixture was subjected to native 6% polyacrylamide gel electrophoresis (acrylamide: bis acrylamide = 19:1). The radioactive RNA was visualized with the Image Reader FLA-9000 and quantified by Multi Gauge V 3.11 software.

### 3.6. Cell Lines

The following Huh-7-derived cell lines used in this study were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 0.5 mg/mL G418: The Lunet/Con1 LUN Sb #26 cell line, which harbors the subgenomic replicon RNA of the Con1 strain (genotype 1b) [34]; the Huh7/ORN3-5B #24 cell line, which harbors the subgenomic replicon RNA of the O strain (genotype 1b) [35]; the Huh7 Rep Feo cell line, which harbors the subgenomic replicon RNA of the N strain (genotype 1b) [33]; and the OR6 cell line, which harbors the full genomic RNA of the O strain (genotype 1b) [35].

### 3.7. Determination of Luciferase Activity in HCV Replicon Cells

HCV replicon cells were seeded at  $2 \times 10^4$  cells per well in a 48-well plate 24 h before treatment. The extract SG1-23-1 was added to the culture medium at various concentrations. The treated cells were harvested 72 h post-treatment and lysed in cell culture lysis reagent (Promega) or *Renilla* luciferase assay lysis buffer (Promega). Luciferase activity in the harvested cells was estimated with a luciferase assay system (Promega) or a *Renilla* luciferase assay system (Promega). The resulting luminescence was detected by the Luminescencer-JNR AB-2100 (ATTO, Tokyo, Japan) and corresponded to the expression level of the HCV replicon.

### 3.8. Determination of Cytotoxicity in HCV Replicon Cells

HCV replicon cells were seeded at a density of  $1 \times 10^4$  cells per well in a 96-well plate and incubated at 37 °C for 24 h. The extract fraction of the sample code SG1-23-1 was added to the culture medium at various concentrations. These cells were treated with an indicated concentration of the extract fraction and then were harvested 72 h post-treatment. Cell viability was measured by dimethylthiazol carboxymethoxy-phenylsulfophenyl tetrazolium (MTS) assay using a CellTiter 96 aqueous one-solution cell proliferation assay kit (Promega).

### 3.9. Effects on Activities of Luciferase and Internal Ribosome Entry Site (IRES)

The plasmid pEF Fluc IN and pEF Rluc EMCV IRES Feo were described previously [41]. The firefly luciferase gene was replaced with the *Renilla* luciferase gene in the plasmid pEF Fluc IN. The resulting plasmid was designated as pEF RlucIN in this study. The Huh7 cells were transfected with the pEF Fluc IN, pEF Rluc IN, or pEF Rluc EMCV IRES Feo and then were established in a medium containing 0.25 mg/mL G418 as described previously [41]. These cell lines were seeded at  $2 \times 10^4$  cells per well in a 48-well plate 24 h before treatment, treated with 50 µg/mL extract SG1-23-1, and then harvested at 72 h post-treatment. Activities of firefly and *Renilla* luciferases in pEF Rluc EMCV IRES Feo were measured with the dual luciferase reporter assay system (Promega). Total protein concentration was measured using the BCA Protein Assay Reagent Kit (Thermo Scientific, Rockford, IL, USA) to normalize luciferase activity.

### 3.10. Western Blotting

The cells were lysed in lysis buffer containing Cell Culture Lysis Reagent (Promega). The cell lysate was subjected to SDS-10% polyacrylamide gel (SDS-PAGE). The proteins in the gel were transferred onto a polyvinylidene fluoride (PVDF) membrane. The resulting membrane was incubated with the primary antibodies at 4 °C overnight and then was washed three times with PBS containing 0.02% Tween 20 (PBS-T). The resulting membrane was reacted with a horseradish peroxidase-labeled anti-IgG antibody at room temperature for 2 h and then was washed three times with PBS-T. The reacted proteins were visualized with ImmunoStar LD (Wako Pure Chemical, Osaka, Japan). The antibodies to NS3 (Abcam, Cambridge, UK), NS5A (ViroGen, Watertown, MA, USA) and beta-actin were purchased from New England Biolabs (Beverly, MA, USA) and were used as the primary antibodies in this study.

### 3.11. Reverse-Transcription Polymerase Chain Reaction (RT-PCR)

The previously described method of RT-PCR [41] was slightly modified, as described below. Total RNA was isolated from cultured cells with the RNAqueous-4PCR kit (Ambion, Austin, TX, USA) and then was reverse-transcribed with a Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The transcribed mRNA was amplified with PCR using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA) and an appropriate primer pair. Primer sequences targeting the genes encoding 2',5'-oligoadenylate synthetase (2',5'-OAS), myxovirus resistance protein A (MxA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were described previously [41].

#### 4. Conclusions

In conclusion, we showed that the ethyl acetate extract from *Alloeocomatella polycladia* significantly inhibits HCV replication by suppressing viral helicase activity. The purification of an inhibitory compound from the extract of *Alloeocomatella polycladia* will be required in order to improve the efficacy of chemical modification of the compound(s).

#### Acknowledgments

We thank R. Bartenschlager for kindly providing cell lines and plasmids, and H. Kasai and I. Katoh for their helpful comments and discussions. This work was supported in part by grants-in-aid from the Ministry of Health, Labor (H22-kanen-004, 006 and 009), and Welfare and from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

#### References

1. Baldo, V.; Baldovin, T.; Trivello, R.; Floreani, A. Epidemiology of HCV infection. *Curr. Pharm. Des.* **2008**, *14*, 1646–1654.
2. Seeff, L.B. Natural history of chronic hepatitis C. *Hepatology* **2002**, *36*, S35–S46.
3. Moriishi, K.; Matsuura, Y. Host factors involved in the replication of hepatitis C virus. *Rev. Med. Virol.* **2007**, *17*, 343–354.
4. Tsukiyama-Kohara, K.; Iizuka, N.; Kohara, M.; Nomoto, A. Internal ribosome entry site within hepatitis C virus RNA. *J. Virol.* **1992**, *66*, 1476–1483.
5. Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. *J. Virol.* **1993**, *67*, 3835–3844.
6. Kim, D.W.; Gwack, Y.; Han, J.H.; Choe, J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. *Biochem. Biophys. Res. Commun.* **1995**, *215*, 160–166.
7. Failla, C.; Tomei, L.; de Francesco, R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. *J. Virol.* **1994**, *68*, 3753–3760.
8. Belon, C.A.; Frick, D.N. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. *Future Virol.* **2009**, *4*, 277–293.
9. Frick, D.N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. *Curr. Issues Mol. Biol.* **2007**, *9*, 1–20.
10. Kwong, A.D.; Rao, B.G.; Jeang, K.T. Viral and cellular RNA helicases as antiviral targets. *Nat. Rev. Drug Discov.* **2005**, *4*, 845–853.
11. Manns, M.P.; Wedemeyer, H.; Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. *Gut* **2006**, *55*, 1350–1359.
12. McHutchison, J.G.; Everson, G.T.; Gordon, S.C.; Jacobson, I.M.; Sulkowski, M.; Kauffman, R.; McNair, L.; Alam, J.; Muir, A.J.; Team, P.S. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N. Engl. J. Med.* **2009**, *360*, 1827–1838.

13. Zeuzem, S.; Hultcrantz, R.; Bourliere, M.; Goeser, T.; Marcellin, P.; Sanchez-Tapias, J.; Sarrazin, C.; Harvey, J.; Brass, C.; Albrecht, J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. *J. Hepatol.* **2004**, *40*, 993–999.
14. Asselah, T.; Marcellin, P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. *Liver Int.* **2011**, *31 Suppl 1*, 68–77.
15. Jazwinski, A.B.; Muir, A.J. Direct-acting antiviral medications for chronic hepatitis C virus infection. *Gastroenterol. Hepatol. (NY)* **2011**, *7*, 154–162.
16. Lange, C.M.; Sarrazin, C.; Zeuzem, S. Review article: specifically targeted anti-viral therapy for hepatitis C—A new era in therapy. *Aliment. Pharmacol. Ther.* **2010**, *32*, 14–28.
17. Hofmann, W.P.; Zeuzem, S. A new standard of care for the treatment of chronic HCV infection. *Nat. Rev. Gastroenterol. Hepatol.* **2011**, *8*, 257–264.
18. Kwong, A.D.; Kauffman, R.S.; Hurter, P.; Mueller, P. Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. *Nat. Biotechnol.* **2011**, *29*, 993–1003.
19. Kieffer, T.L.; Kwong, A.D.; Picchio, G.R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). *J. Antimicrob. Chemother.* **2010**, *65*, 202–212.
20. Thompson, A.J.; McHutchison, J.G. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). *J. Viral. Hepat.* **2009**, *16*, 377–387.
21. Belon, C.A.; High, Y.D.; Lin, T.I.; Pauwels, F.; Frick, D.N. Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. *Biochemistry* **2010**, *49*, 1822–1832.
22. Maga, G.; Gemma, S.; Fattorusso, C.; Locatelli, G.A.; Butini, S.; Persico, M.; Kukreja, G.; Romano, M.P.; Chiasserini, L.; Savini, L.; *et al.* Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. *Biochemistry* **2005**, *44*, 9637–9644.
23. Chin, Y.W.; Balunas, M.J.; Chai, H.B.; Kinghorn, A.D. Drug discovery from natural sources. *AAPS J.* **2006**, *8*, E239–E253.
24. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. *Nat. Rev. Drug Discov.* **2005**, *4*, 206–220.
25. Li, J.W.; Vederas, J.C. Drug discovery and natural products: End of an era or an endless frontier? *Science* **2009**, *325*, 161–165.
26. Ahmed-Belkacem, A.; Ahnou, N.; Barbotte, L.; Wychowski, C.; Pallier, C.; Brillet, R.; Pohl, R.T.; Pawlotsky, J.M. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. *Gastroenterology* **2010**, *138*, 1112–1122.
27. Wagoner, J.; Negash, A.; Kane, O.J.; Martinez, L.E.; Nahmias, Y.; Bourne, N.; Owen, D.M.; Grove, J.; Brimacombe, C.; McKeating, J.A.; *et al.* Multiple effects of silymarin on the hepatitis C virus lifecycle. *Hepatology* **2010**, *51*, 1912–1921.
28. Ciesek, S.; von Hahn, T.; Colpitts, C.C.; Schang, L.M.; Friesland, M.; Steinmann, J.; Manns, M.P.; Ott, M.; Wedemeyer, H.; Meuleman, P.; *et al.* The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. *Hepatology* **2011**, *54*, 1947–1955.

29. Takeshita, M.; Ishida, Y.; Akamatsu, E.; Ohmori, Y.; Sudoh, M.; Uto, H.; Tsubouchi, H.; Kataoka, H. Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. *J. Biol. Chem.* **2009**, *284*, 21165–21176.
30. Donia, M.; Hamann, M.T. Marine natural products and their potential applications as anti-infective agents. *Lancet Infect. Dis.* **2003**, *3*, 338–348.
31. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products. *Nat. Rev. Drug Discov.* **2009**, *8*, 69–85.
32. Mayer, A.M.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: A current pipeline perspective. *Trends Pharmacol. Sci.* **2010**, *31*, 255–265.
33. Yokota, T.; Sakamoto, N.; Enomoto, N.; Tanabe, Y.; Miyagishi, M.; Maekawa, S.; Yi, L.; Kurosaki, M.; Taira, K.; Watanabe, M.; *et al.* Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. *EMBO Rep.* **2003**, *4*, 602–608.
34. Frese, M.; Barth, K.; Kaul, A.; Lohmann, V.; Schwarzle, V.; Bartenschlager, R. Hepatitis C virus RNA replication is resistant to tumour necrosis factor- $\alpha$ . *J. Virol.* **2003**, *84*, 1253–1259.
35. Ikeda, M.; Abe, K.; Dansako, H.; Nakamura, T.; Naka, K.; Kato, N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem. Biophys. Res. Commun.* **2005**, *329*, 1350–1359.
36. Blight, K.J.; Kolykhalov, A.A.; Rice, C.M. Efficient initiation of HCV RNA replication in cell culture. *Science* **2000**, *290*, 1972–1974.
37. Guo, J.T.; Bichko, V.V.; Seeger, C. Effect of alpha interferon on the hepatitis C virus replicon. *J. Virol.* **2001**, *75*, 8516–8523.
38. Tani, H.; Akimitsu, N.; Fujita, O.; Matsuda, Y.; Miyata, R.; Tsuneda, S.; Igarashi, M.; Sekiguchi, Y.; Noda, N. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. *Biochem. Biophys. Res. Commun.* **2009**, *379*, 1054–1059.
39. Gallinari, P.; Brennan, D.; Nardi, C.; Brunetti, M.; Tomei, L.; Steinkuhler, C.; De Francesco, R. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. *J. Virol.* **1998**, *72*, 6758–6769.
40. Huang, Y.; Liu, Z.R. The ATPase, RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase. *J. Biol. Chem.* **2002**, *277*, 12810–12815.
41. Jin, H.; Yamashita, A.; Maekawa, S.; Yang, P.; He, L.; Takayanagi, S.; Wakita, T.; Sakamoto, N.; Enomoto, N.; Ito, M. Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication *in vitro*. *Hepatol. Res.* **2008**, *38*, 909–918.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).



201227006B (3/2)

厚生労働科学研究費補助金  
肝炎等克服緊急対策研究事業

ウイルス性肝炎の病態に応じたウイルス側  
因子の解明と治療応用に関する研究

平成22年度～平成24年度 総合研究報告書Ⅱ

研究代表者 榎本 信幸

平成25(2013)年3月



Contents lists available at SciVerse ScienceDirect

Virus Research

journal homepage: [www.elsevier.com/locate/virusres](http://www.elsevier.com/locate/virusres)



Short communication

## Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a

Fuminori Sakurai<sup>a</sup>, Norihisa Furukawa<sup>b</sup>, Maiko Higuchi<sup>b</sup>, Sayuri Okamoto<sup>a</sup>, Kaori Ono<sup>a</sup>, Takeshi Yoshida<sup>c</sup>, Masuo Kondoh<sup>c</sup>, Kiyohito Yagi<sup>c</sup>, Naoya Sakamoto<sup>d</sup>, Kazufumi Katayama<sup>a</sup>, Hiroyuki Mizuguchi<sup>a,b,e,\*</sup>

<sup>a</sup> Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

<sup>b</sup> Laboratory of Stem cell Regulation, National Institute of Biomedical Innovation, Osaka, Japan

<sup>c</sup> Laboratory of Bio-functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

<sup>d</sup> Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

<sup>e</sup> The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan

### ARTICLE INFO

#### Article history:

Received 5 December 2011

Received in revised form 27 January 2012

Accepted 3 February 2012

Available online xxx

#### Keywords:

Adenovirus vector

Tough decoy RNA

miR-122a

Hepatitis C virus

microRNA

### ABSTRACT

Recent studies have demonstrated that the liver-specific microRNA (miRNA) miR-122a plays an important role in the replication of hepatitis C virus (HCV). Antisense nucleotides against miR-122a, including locked nucleic acid (LNA), have shown promising results for suppression of HCV replication; however, a liver-specific delivery system of antisense nucleotides has not been fully developed. In this study, an adenovirus (Ad) vector that expresses tough decoy (TuD)-RNA against miR-122a (TuD-122a) was developed to suppress the HCV replication in the liver hepatocytes. Ad vectors have been well established to exhibit a marked hepatotropism following systemic administration. An in vitro reporter gene expression assay demonstrated that Ad vector-mediated expression of TuD-122a efficiently blocked the miR-122a in Huh-7 cells. Furthermore, transduction with the Ad vector expressing TuD-122a in HCV replicon-expressing cells resulted in significant reduction in the HCV replicon levels. These results indicate that Ad vector-mediated expression of TuD-122a would be a promising tool for treatment of HCV infection.

© 2012 Elsevier B.V. All rights reserved.


Hepatitis C virus (HCV) is a hepatotropic human virus belonging to a member of the family *Flaviviridae* and possessing a 9.6-kb positive-sense RNA genome. HCV infection causes chronic hepatic inflammation and fibrosis, leading to hepatocellular carcinoma (Hoofnagle, 2002). Currently, 170 million people worldwide are infected with HCV, and suffering from or at risk for the diseases described above. In order to suppress the replication of HCV, PEGylated interferon alpha and ribavirin, which is a nucleotide analogue, have been used as standard-of-care therapy; however, the therapeutic efficiency has been limited, in spite of relatively severe side effects, including fever and malaise (Chisari, 2005; Feld and Hoofnagle, 2005). Another therapeutic strategy should be developed to efficiently suppress the HCV infection and HCV-caused diseases.

Among several host factors involved in HCV infection, the abundant liver-specific microRNA (miRNA), miR-122a has been demonstrated to be crucial for efficient replication and/or

translation of the HCV genome (Henke et al., 2008; Jopling et al., 2005; Randall et al., 2007). The HCV genome has two closely spaced miR-122a-binding sites in the 5'-untranslated region (UTR), which contains overlapping *cis*-acting signals involved in translation and RNA synthesis (Jopling et al., 2005). Although the mechanism of the miR-122a-mediated enhancement of HCV replication is controversial (Henke et al., 2008; Jopling et al., 2005; Machlin et al., 2011; Roberts et al., 2011; Wilson et al., 2011), antisense oligonucleotides complementary to miR-122a, including locked nucleic acid (LNA) oligonucleotides, have been shown to significantly inhibit miR-122a and reduce the HCV genome, and thereby to exhibit superior therapeutic effects (Henke et al., 2008; Jopling et al., 2005; Krutzfeldt et al., 2005; Lanford et al., 2010). Intravenous administration of LNA oligonucleotides against miR-122a into HCV-infected chimpanzees resulted in the long-lasting suppression of HCV viremia without viral resistance or severe side effects (Lanford et al., 2010). In addition, the 5'-UTR of the HCV genome is composed of highly conserved structural domains, suggesting that a mutant lacking the miR-122a-binding sites in the genome is unlikely to appear. These results indicate that miR-122a is a promising target for the treatment of HCV-related diseases; however, LNA oligonucleotides accumulate in the kidney immediately after intravenous administration and are excreted into the urine (Fluiter et al., 2003).

\* Corresponding author at: Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel.: +81 6 6879 8185; fax: +81 6 6879 8186.

E-mail address: [mizuguch@phs.osaka-u.ac.jp](mailto:mizuguch@phs.osaka-u.ac.jp) (H. Mizuguchi).



**Fig. 1.** Structure of Ad vectors used in this study. The human U6 promoter-driven TuD-RNA expression cassette was inserted into the E1-deleted region of the Ad vector genome. The CMV promoter-driven GFP expression cassette was inserted into the E3-deleted region of the Ad vector genome.


Systems which efficiently deliver or express anti-miR-122a drugs in the liver are necessary to efficiently treat HCV-related diseases.

Recently, tough decoy (TuD)-RNAs against miRNAs, which efficiently and specifically inhibit miRNAs, were developed by Haraguchi et al. (2009). TuD-RNAs are composed of two miRNA-binding sequence (MBS) regions and two stem structures with 3-nucleotide linkers. The MBS in the TuD-RNA is considered to tightly bind to miRNAs, leading to the inhibition of miRNAs. The inhibition activity of the TuD-RNA against miRNAs is higher than that of LNA oligonucleotides and miRNA sponges (Haraguchi et al., 2009). Another advantage of the TuD-RNA is that it can be expressed by viral and non-viral vectors. miRNAs can be persistently suppressed by lentivirus vector- and retrovirus vector-mediated expression of the TuD-RNA. Furthermore, liver-specific expression of the TuD-RNA is thought to be achievable by an adenovirus (Ad) vector and adeno-associated virus vector, because these vectors can express transgenes in a liver-specific manner after systemic administration. These properties of the TuD-RNA are highly promising for inhibition of miR-122a in the liver and suppression of HCV replication.

In the present study, we developed an Ad vector expressing the TuD-RNA against miR-122a (TuD-122a) to efficiently inhibit miR-122a and to suppress the HCV replication. Transduction with an Ad vector expressing TuD-122a efficiently inhibited miR-122a *in vitro*. In HCV replicon-expressing cells, HCV replicon levels were significantly reduced by Ad vector-mediated TuD-122a expression.

First, in order to examine the transduction efficiencies of the Ad vectors constructed in this study in the HCV replicon-expressing cells, Huh-7.5.1 1bFeo cells, which is a genotype 1b HCV replicon cell line (Yokota et al., 2003), were transduced with an Ad vector expressing TuD-122a (Ad-TuD-122a) or the control TuD-RNA (Ad-TuD-NC). Ad-TuD-122a and Ad-TuD-NC were prepared as described in Supplemental materials and methods. Structure of Ad vectors used in this study is shown in Fig. 1. The ratio of particles-to-biological titer was between 6 and 9 for each Ad vector used in this study. Both Ad-TuD-122a and Ad-TuD-NC carry the TuD-RNA expression cassette and the green fluorescence protein (GFP) expression cassette in the E1-deleted and E3-deleted region, respectively (Fig. 1). Both Ad-TuD-NC and Ad-TuD-122a efficiently transduced Huh-7.5.1 1bFeo cells (Fig. 2). More than 80% of the cells were found to be GFP-positive following transduction with Ad-TuD-122a and Ad-TuD-NC, respectively, at a multiplicity of infection (MOI) of 100. The averages of GFP-positive cells following transduction with Ad-TuD-NC were slightly higher than those with Ad-TuD-122a; however, statistically significant differences were not found for either group. Apparent cellular toxicity was not found following transduction with Ad-TuD-122a or Ad-TuD-NC (data not shown). These results indicate that Ad-TuD-122a and Ad-TuD-NC efficiently transduce Huh-7.5.1 1bFeo cells.


Next, in order to examine the inhibitory effects of TuD-122a expressed by the Ad vector on miR-122a, a reporter gene assay using the miR-122a complementary sequence-encoded plasmid, psiCheck-122aT, was performed in Huh-7 cells. Huh-7 cells endogenously express a high level of miR-122a (Suzuki et al., 2008). Huh-7 cells were transduced with the Ad vectors at MOIs of 25 and 100 for 1.5 h. After a 24-h incubation, the cells were transfected with



**Fig. 2.** Transduction efficiencies of Ad-TuD-122a and Ad-TuD-NC in Huh-7.5.1 1bFeo cells. The cells were transduced with Ad-TuD-122a or Ad-TuD-NC at multiplicities of infection (MOIs) of 25, 50, and 100 for 1.5 h. At 48 h after transduction, GFP expression was evaluated by flow cytometry. The data are expressed as the means  $\pm$  S.D. ( $n=3$ ). The percentage of GFP-positive cells in the mock-transduced group was less than 0.2%. N.S.: not significant.

psiCheck-2 or psiCheck-122aT. The renilla and firefly luciferase expression was evaluated 48 h after transfection with the plasmid DNA. psiCheck-122aT, plasmid DNA containing the two copies of miR-122a complementary sequences in the 3'-UTR of the renilla luciferase gene, was constructed by ligation of *NotI/XhoI*-digested psiCheck-2 (Promega, Madison, WI) with the oligonucleotides 122aT-F and 122aT-R. The sequences of the oligonucleotides 122aT-F and 122aT-R are described in the Supplemental information. In mock-transduced cells, the relative renilla luciferase expression level by psiCheck-122aT was about 5-fold lower than that by the control plasmid psiCheck-2, which does not possess miR-122a target sequences, due to the endogenous expression of miR-122a in Huh-7 cells (Fig. 3). The renilla luciferase expression profiles following transfection with psiCheck-122aT were similar in the mock-transduced cells and Ad-TuD-NC-transduced cells, indicating that expression of the control TuD-RNA does not inhibit the miR-122a. Ad-TuD-122a did not alter the renilla luciferase expression level by psiCheck-2; on the other hand, psiCheck-122aT-mediated renilla luciferase expression was significantly restored by Ad-TuD-122a. The cells transduced with Ad-TuD-122a exhibited 2.8-fold and 3.5-fold higher renilla luciferase expression at MOIs of 25 and 100, respectively, than the mock-transduced cells following transfection with psiCheck-122aT. These results indicate that miR-122a is efficiently inhibited by Ad-TuD-122a. We also performed quantitative RT-PCR analysis for miR-122a following transduction with Ad-TuD-122a and Ad-TuD-NC in Huh-7 cells. No significant differences in the miR-122a expression levels were found in the cells transduced with Ad-TuD-122a and the cells transduced with Ad-TuD-NC (data not shown), probably because TuD-RNA does not induce degradation of miRNA, although TuD-RNA tightly binds to the target miRNA (Haraguchi et al., 2009).

Next, in order to examine whether TuD-122a-mediated inhibition of miR-122a suppresses the HCV replicon, Huh-7.5.1 1bFeo cells were transduced with Ad-TuD-122a and Ad-TuD-NC at the indicated MOIs. Huh-7.5.1 1bFeo cells express an mRNA consisting of the HCV 5'-UTR and the upstream part of the core region, connected in-frame with the firefly luciferase gene, which allows the simple evaluation of the HCV replicon levels by measuring the firefly luciferase activity in the cells (Yokota et al., 2003). Huh-7.5.1 1bFeo cells were transduced with the Ad vectors at MOIs of 25, 50, and 100 for 1.5 h. After a total 48-h incubation,



**Fig. 3.** Inhibition of miR-122a by Ad vector-mediated TuD-122a expression. (A) Structure of the reporter gene-expressing plasmids psiCheck-2 and psiCheck-122aT. (B and C) Relative renilla luciferase expression levels following transduction with Ad-TuD-NC or Ad-TuD-122a at MOIs of 25 (B) and 100 (C). The data are expressed as the means  $\pm$  S.D. ( $n = 4$ ).


firefly luciferase expression levels were determined. Ad-TuD-122a significantly reduced the firefly luciferase expression levels in a dose-dependent manner (Fig. 4a). The firefly luciferase expression level was reduced to 29% of that in the cells transduced with Ad-TuD-NC at MOI of 100 by transduction with Ad-TuD-122a at MOI of 100. In contrast, no significant changes in the firefly luciferase expression were found by transduction with Ad-TuD-NC.

To examine whether inhibition of miR-122a by Ad vector-mediated TuD-122a expression leads to a reduction in HCV replicon RNA levels, strand-specific real-time RT-PCR analysis was performed to determine the HCV replicon RNA levels. Briefly, Huh-7.5.1 1bFeo cells were transduced with the Ad vectors as described above, and the total RNA was isolated 48 h after transduction. Real-time RT-PCR analysis for the HCV positive-strand RNA genome was performed as follows. Briefly, 2  $\mu$ g of total RNA was reverse-transcribed to cDNA using the primer specific for the HCV positive-strand genome (RC21; 5'-ctc ccg ggg cac tcg caa gc-3'). Real-time RT-PCR was performed using the primers (RC21 and RC1; 5'-gtc tag cca tgg cgt tag ta-3') and SYBR Premix Ex Taq II (Takara Bio Inc., Kyoto, Japan). Similarly to the results for the firefly luciferase expression in Fig. 4A, HCV replicon RNA levels were significantly reduced by Ad-TuD-122a (Fig. 4B). There was an approximately 2.2-fold decline in the HCV replicon RNA level in the cells transduced with Ad-TuD-122a at an MOI of 100, compared with the HCV replicon RNA level in the cells transduced with Ad-TuD-NC at an MOI of 100. Ad-TuD-NC did not apparently decrease the HCV replicon RNA levels. These results indicate that the inhibition of miR-122a by Ad vector-mediated TuD-122a expression efficiently suppresses the replication of the HCV replicon.

The present study demonstrates that Ad vector-mediated TuD-122a expression significantly inhibits the function of miR-122a and

replication of the HCV replicon. Replication of the HCV genome is promoted by the direct interaction between miR-122a and the complementary sequences in the 5'-UTR of the HCV genome (Henke et al., 2008; Jangra et al., 2010), indicating that sequestration of miR-122a leads to suppression of the HCV replication. In order to suppress the HCV replicon by inhibiting miR-122a, TuD-RNA was selected as an inhibitor of miRNA in this study, because TuD-RNA potentially inhibits miRNA by strongly binding to miRNA (Haraguchi et al., 2009). In addition, TuD-RNA can be expressed by conventional gene delivery vectors, including virus vectors. One drawback of TuD-RNA is that TuD-RNA does not discriminate miRNA members that belong to the same miRNA family (Haraguchi et al., 2009); however, miR-122a does not constitute a family of miRNAs, suggesting that TuD-122a would not inhibit other miRNAs.

As described above, an Ad vector is suitable for liver-specific expression of TuD-RNA due to the strong hepatotropism. Previous studies demonstrated that Ad vectors expressing short-hairpin RNA (shRNA) or antisense RNA against the HCV genome successfully exhibited the suppressive effects on HCV infection in vivo (Gonzalez-Carmona et al., 2011; Sakamoto et al., 2008). Another advantage of using an Ad vector for treatment of HCV-related diseases is that in vivo administration of an Ad vector induces type I interferon (IFN) production via innate immune responses (Huarte et al., 2006; Zhu et al., 2007). Our group previously demonstrated that VA-RNA, which is a small non-coding RNA expressed from a replication-incompetent Ad vector as well as wild-type Ad, stimulates type I IFN production in an IFN- $\beta$  promoter stimulator-1 (IPS-1)-dependent manner (Yamaguchi et al., 2010). Ad vector-induced type I IFN would contribute to suppression of HCV infection. The anti-HCV activity of Ad-TuD-122a can also be up-regulated by insertion of an expression cassette of an



**Fig. 4.** Suppression of the HCV replicon by Ad vector-mediated TuD-122a expression. (A) Firefly luciferase expression levels and (B) HCV replicon RNA levels in Huh-7.5.1 1bFeo cells following transduction with the Ad vectors. All the data are shown as the means  $\pm$  S.D. ( $n=3$ ). N.S.: not significant. \* $P<0.05$ , \*\* $P<0.005$  between mock-transduced cells and cells transduced with Ad-TuD-122a.

anti-HCV gene, including type I IFN genes and short-hairpin RNA (shRNA) or antisense RNA against the HCV genome, into the Ad vector genome. Our group has developed various types of Ad vectors in which two or three transgene expression cassettes can be inserted into a single Ad vector genome (Mizuguchi et al., 2001, 2005, 2003).

Previous studies have demonstrated that lipid droplets, which are lipid-storage intracellular organelles, are crucial for the production of infectious HCV particles (Hinson and Cresswell, 2009; Miyanari et al., 2007). Miyanari et al. demonstrated that HCV capsid proteins recruit the non-structural proteins and the replication complex to the lipid droplet-associated membrane (Miyanari et al., 2007). miR-122a is an important factor that regulates cholesterol and fatty-acid metabolism in the hepatocytes (Esau et al., 2006; Iliopoulos et al., 2010). Intravenous administration of the antisense oligonucleotide against miR-122a resulted in a reduction in the plasma levels of cholesterol and triglycerides (Esau et al., 2006; Lanford et al., 2010). In addition to the enhancement of accumulation and translation of the HCV genome, miR-122a might up-regulate HCV infection by regulating lipid metabolism in the hepatocytes.

Almost similar levels of reduction in the HCV replicon RNA copy numbers were found for Ad-TuD-122a at MOIs of 25, 50, and 100, although there was dose-dependent reduction in the firefly luciferase expression following transduction with Ad-TuD-122a. It remains unclear why dose-dependent reduction in the HCV replicon RNA copy numbers was not found, however, miR-122a plays a crucial role in the enhancement of both translation and stability of HCV genome (Henke et al., 2008; Jopling et al., 2005; Randall et al., 2007; Shimakami et al., 2012). Stability of HCV genome might be more susceptible to inhibition of miR-122a than translation. The averages of HCV replicon RNA levels were also reduced following transduction with Ad-TuD-NC, although

statistically significant differences were not found, compared with the mock-transduced cells. Replication-incompetent Ad vectors express non-coding small RNA (VA-RNA), which forms RNA-induced silencing complex (RISC) with argonaute 2 (Ago2) (Xu et al., 2007). Ago2 is an important factor for miRNA processing (Diederichs and Haber, 2007). Processing of miR-122a might be slightly disturbed by Ad vector-expressed VA-RNA, leading to the reduction in the HCV replicon RNA levels.

In summary, we efficiently suppressed the HCV replicon levels by Ad vector-mediated expression of TuD-122a, which blocks the function of miR-122a. This study indicates that Ad vector-mediated expression of TuD-122a in liver hepatocytes would offer an alternative approach for the treatment of HCV infection.

### Conflict of interest

The authors declare no conflict of interest.

### Acknowledgements

This study was supported by grants from the Ministry of Health, Labor and Welfare of Japan (to F.S.).

### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.virusres.2012.02.003.

### References

- Chisari, F.V., 2005. Unscrambling hepatitis C virus–host interactions. *Nature* 436 (7053), 930–932.
- Diederichs, S., Haber, D.A., 2007. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. *Cell* 131 (6), 1097–1108.
- Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., Watts, L., Booten, S.L., Graham, M., McKay, R., Subramaniam, A., Propp, S., Lollo, B.A., Freier, S., Bennett, C.F., Bhanot, S., Monia, B.P., 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. *Cell Metab.* 3 (2), 87–98.
- Feld, J.J., Hoofnagle, J.H., 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 436 (7053), 967–972.
- Fluiter, K., ten Asbroek, A.L., de Wissel, M.B., Jakobs, M.E., Wissenbach, M., Olsson, H., Olsen, O., Oerum, H., Baas, F., 2003. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. *Nucleic Acids Res.* 31 (3), 953–962.
- Gonzalez-Carmona, M.A., Vogt, A., Heinicke, T., Quasdorff, M., Hoffmann, P., Yildiz, Y., Schneider, C., Serwe, M., Bartenschlager, R., Sauerbruch, T., Caselmann, W.H., 2011. Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA in vitro and in vivo. *J. Hepatol.* 55 (1), 19–28.
- Haraguchi, T., Ozaki, Y., Iba, H., 2009. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. *Nucleic Acids Res.* 37 (6), e43.
- Henke, J.I., Goergen, D., Zheng, J., Song, Y., Schuttler, C.G., Fehr, C., Junemann, C., Niepmann, M., 2008. microRNA-122 stimulates translation of hepatitis C virus RNA. *EMBO J.* 27 (24), 3300–3310.
- Hinson, E.R., Cresswell, P., 2009. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. *Proc. Natl. Acad. Sci. U.S.A.* 106 (48), 20452–20457.
- Hoofnagle, J.H., 2002. Course and outcome of hepatitis C. *Hepatology* 36 (5 Suppl 1), S21–S29.
- Huarte, E., Larrea, E., Hernandez-Alcoceba, R., Alfaro, C., Murillo, O., Arina, A., Tirapu, I., Azpilicueta, A., Hervas-Stubbs, S., Bortolanza, S., Perez-Gracia, J.L., Civeira, M.P., Prieto, J., Riezu-Boj, J.I., Melero, I., 2006. Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. *Mol. Ther.* 14 (1), 129–138.
- Iliopoulos, D., Drosatos, K., Hiyama, Y., Goldberg, I.J., Zannis, V.I., 2010. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. *J. Lipid Res.* 51 (6), 1513–1523.
- Jangra, R.K., Yi, M., Lemon, S.M., 2010. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. *J. Virol.* 84 (13), 6615–6625.
- Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M., Sarnow, P., 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science* 309 (5740), 1577–1581.
- Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., Stoffel, M., 2005. Silencing of microRNAs in vivo with 'antagomirs'. *Nature* 438 (7068), 685–689.

- Lanford, R.E., Hildebrandt-Eriksen, E.S., Petri, A., Persson, R., Lindow, M., Munk, M.E., Kauppinen, S., Orum, H., 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. *Science* 327 (5962), 198–201.
- Machlin, E.S., Sarnow, P., Sagan, S.M., 2011. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA–target RNA complex. *Proc. Natl. Acad. Sci. U.S.A.* 108 (8), 3193–3198.
- Miyanari, Y., Atsuzawa, K., Usuda, N., Watashi, K., Hishiki, T., Zayas, M., Bartenschlager, R., Wakita, T., Hijikata, M., Shimotohno, K., 2007. The lipid droplet is an important organelle for hepatitis C virus production. *Nat. Cell Biol.* 9 (9), 1089–1097.
- Mizuguchi, H., Kay, M.A., Hayakawa, T., 2001. In vitro ligation-based cloning of foreign DNAs into the E3 and E1 deletion regions for generation of recombinant adenovirus vectors. *Biotechniques* 30 (5), 1112–1114, 1116.
- Mizuguchi, H., Xu, Z.L., Sakurai, F., Kawabata, K., Yamaguchi, T., Hayakawa, T., 2005. Efficient regulation of gene expression using self-contained fiber-modified adenovirus vectors containing the tet-off system. *J. Control. Release* 110 (1), 202–211.
- Mizuguchi, H., Xu, Z.L., Sakurai, F., Mayumi, T., Hayakawa, T., 2003. Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. *Hum. Gene Ther.* 14 (13), 1265–1277.
- Randall, G., Panis, M., Cooper, J.D., Tellinghuisen, T.L., Sukhodolets, K.E., Pfeffer, S., Landthaler, M., Landgraf, P., Kan, S., Lindenbach, B.D., Chien, M., Weir, D.B., Russo, J.J., Ju, J., Brownstein, M.J., Sheridan, R., Sander, C., Zavolan, M., Tuschl, T., Rice, C.M., 2007. Cellular cofactors affecting hepatitis C virus infection and replication. *Proc. Natl. Acad. Sci. U.S.A.* 104 (31), 12884–12889.
- Roberts, A.P., Lewis, A.P., Jopling, C.L., 2011. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. *Nucleic Acids Res.*
- Sakamoto, N., Tanabe, Y., Yokota, T., Satoh, K., Sekine-Osajima, Y., Nakagawa, M., Itsui, Y., Tasaka, M., Sakurai, Y., Cheng-Hsin, C., Yano, M., Ohkoshi, S., Aoyagi, Y., Maekawa, S., Enomoto, N., Kohara, M., Watanabe, M., 2008. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. *J. Gastroenterol. Hepatol.* 23 (9), 1437–1447.
- Shimakami, T., Yamane, D., Jangra, R.K., Kempf, B.J., Spaniel, C., Barton, D.J., Lemon, S.M., 2012. Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex. *Proc. Natl. Acad. Sci. U.S.A.*
- Suzuki, T., Sakurai, F., Nakamura, S., Kouyama, E., Kawabata, K., Kondoh, M., Yagi, K., Mizuguchi, H., 2008. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. *Mol. Ther.* 16 (10), 1719–1726.
- Wilson, J.A., Zhang, C., Huys, A., Richardson, C.D., 2011. Human Ago2 is required for efficient microRNA 122 regulation of hepatitis C virus RNA accumulation and translation. *J. Virol.* 85 (5), 2342–2350.
- Xu, N., Segerman, B., Zhou, X., Akusjarvi, G., 2007. Adenovirus virus-associated RNAI-derived small RNAs are efficiently incorporated into the RNA-induced silencing complex and associate with polyribosomes. *J. Virol.* 81 (19), 10540–10549.
- Yamaguchi, T., Kawabata, K., Kouyama, E., Ishii, K.J., Katayama, K., Suzuki, T., Kurachi, S., Sakurai, F., Akira, S., Mizuguchi, H., 2010. Induction of type I interferon by adenovirus-encoded small RNAs. *Proc. Natl. Acad. Sci. U.S.A.* 107 (40), 17286–17291.
- Yokota, T., Sakamoto, N., Enomoto, N., Tanabe, Y., Miyagishi, M., Maekawa, S., Yi, L., Kurosaki, M., Taira, K., Watanabe, M., Mizusawa, H., 2003. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. *EMBO Rep.* 4 (6), 602–608.
- Zhu, J., Huang, X., Yang, Y., 2007. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. *J. Virol.* 81 (7), 3170–3180.

## Original Article

# Factors responsible for the discrepancy between *IL28B* polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

Hiroaki Saito,<sup>1,2</sup> Kiyooki Ito,<sup>1</sup> Masaya Sugiyama,<sup>1</sup> Teppei Matsui,<sup>1</sup> Yoshihiko Aoki,<sup>1</sup> Masatoshi Imamura,<sup>1</sup> Kazumoto Murata,<sup>1</sup> Naohiko Masaki,<sup>1</sup> Hideyuki Nomura,<sup>3</sup> Hiroshi Adachi,<sup>4</sup> Shuhei Hige,<sup>5</sup> Nobuyuki Enomoto,<sup>6</sup> Naoya Sakamoto,<sup>7</sup> Masayuki Kurosaki,<sup>8</sup> Masashi Mizokami<sup>1</sup> and Sumio Watanabe<sup>2</sup>

<sup>1</sup>The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, <sup>2</sup>Department of Gastroenterology, Juntendo University School of Medicine, Bunkyo-ku, <sup>3</sup>The Center for Liver Diseases, Shin-Kokura Hospital, Kitakyushu, Fukuoka, <sup>4</sup>Department of Virology and Liver Unit, Tonami General Hospital, Tonami, <sup>5</sup>Department of Internal Medicine, Hokkaido University Graduate School of Medicine, Sapporo, <sup>6</sup>Department of Internal Medicine, University of Yamanashi, Kofu, <sup>7</sup>Department for Hepatitis Control, Tokyo Medical and Dental University, Tokyo, and <sup>8</sup>Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan

**Aim:** *IL28B* polymorphisms serve to predict response to pegylated interferon plus ribavirin therapy (PEG IFN/RBV) in Japanese patients with chronic hepatitis C (CHC) very reliably. However, the prediction by the *IL28B* polymorphism contradicted the virological response to PEG IFN/RBV in some patients. Here, we aimed to investigate the factors responsible for the discrepancy between the *IL28B* polymorphism prediction and virological responses.

**Methods:** CHC patients with genotype 1b and high viral load were enrolled in this study. In a case-control study, clinical and virological factors were analyzed for 130 patients with rs8099917 TT genotype and 96 patients with rs8099917 TG or GG genotype who were matched according to sex, age, hemoglobin level and platelet count.

**Results:** Higher low-density lipoprotein (LDL) cholesterol, lower  $\gamma$ -glutamyltransferase and the percentage of wild-type phenotype at amino acids 70 and 91 were significantly

associated with the rs8099917 TT genotype. Multivariate analysis showed that rs8099917 TG or GG genotype, older age and lower LDL cholesterol were independently associated with the non-virological responder (NVR) phenotype. In patients with rs8099917 TT genotype (predicted as virological responder [VR]), multivariate analysis showed that older age was independently associated with NVR. In patients with rs8099917 TG or GG genotype (predicted as NVR), multivariate analysis showed that younger age was independently associated with VR.

**Conclusion:** Patient age gave rise to the discrepancy between the prediction by *IL28B* polymorphism and the virological responses, suggesting that patients should be treated at a younger age.

**Key words:** aging, genotype, *IL28B*, low-density lipoprotein cholesterol, single nucleotide polymorphism

## INTRODUCTION

**H**EPATITIS C VIRUS (HCV) infection is a global health problem with worldwide estimates of

120–130 million carriers.<sup>1</sup> Chronic HCV infection, the leading cause of liver transplantation, can lead to progressive liver disease, resulting in cirrhosis and complications, including decompensated liver disease and hepatocellular carcinoma.<sup>2</sup> The current standard-of-care treatment for suitable patients with chronic HCV infection consists of pegylated interferon- $\alpha$ -2a or -2b (PEG IFN) given by injection in combination with oral ribavirin (RBV) for 24 or 48 weeks, depending on HCV genotype. Large-scale treatment in the USA and Europe showed that 42–52% of patients with HCV genotype 1

Correspondence: Dr Masashi Mizokami, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba 272-8516, Japan. Email: mmizokami@hospk.ncgm.go.jp

Received 23 February 2012; revision 18 March 2012; accepted 22 March 2012.

achieved a sustained virological response (SVR),<sup>3–5</sup> and studies conducted in Japan produced similar results. This treatment is associated with well-known side-effects (e.g. influenza-like syndrome, hematological abnormalities and neuropsychiatric events) resulting in reduced compliance and fewer patients completing treatment.<sup>6</sup> It is important to predict an individual's response before treatment with PEG IFN/RBV to avoid side-effects, as well as to reduce the treatment cost. The HCV genotype, in particular, is used to predict the response: patients with the HCV genotype 2/3 have a relatively high rate of SVR (70–80%) with 24 weeks of treatment, whereas those infected with genotype 1 have a much lower rate of SVR, despite 48 weeks of treatment.<sup>5</sup>

Our recent genome-wide association studies (GWAS) revealed that several highly correlated common single nucleotide polymorphisms (SNP) in the region of the interleukin-28B (*IL28B*) gene on chromosome 19, coding for interferon (IFN)- $\lambda$ 3, are implicated in the non-virological responder (NVR) to PEG IFN/RBV phenotype among patients infected by HCV genotype 1.<sup>7</sup> The association between response to PEG IFN/RBV and SNP associated with *IL28B* was concurrently reported by two other groups who also employed GWAS.<sup>8,9</sup> The *IL28B* polymorphism was highly predictive of the response to PEG IFN/RBV therapy in Japanese chronic hepatitis C (CHC) patients.<sup>10–12</sup> However, this was not always the case. Therefore, we attempted to determine why the *IL28B* polymorphism did not predict the response of all patients. The nature of the functional link between the *IL28B* polymorphism and HCV clearance is unknown, and this must be defined to understand how the *IL28B* polymorphism correlates with HCV clearance. Therefore, we also investigated the association between the *IL28B* polymorphism and clinical characteristics of CHC patients.

## METHODS

### Patients

A TOTAL OF 696 CHC patients with genotype 1b and high viral load were recruited from the National Center for Global Health and Medicine, Hokkaido University Hospital, Tokyo Medical and Dental University Hospital, Yamanashi University Hospital, Tonami General Hospital, and Shin-Kokura Hospital in Japan. In a case-control study, sex, age, hemoglobin level and platelet count were matched between patients with the rs8099917 TT genotype ( $n = 130$ ) and patients with

rs8099917 TG or GG genotypes ( $n = 96$ ) to eliminate background biases.

Each patient was treated with PEG IFN- $\alpha$ -2b (1.5  $\mu$ g/kg s.c. weekly) or PEG IFN- $\alpha$ -2a (180  $\mu$ g/body s.c. weekly) plus RBV (600–1000 mg daily, depending on bodyweight). Because a reduction in the dose of PEG IFN/RBV can contribute to a lower SVR rate,<sup>13</sup> only patients with an adherence of more than 80% dose for both drugs during the first 12 weeks were included in this study. Those positive for hepatitis B surface antigen and/or anti-HIV were excluded from this study.

Non-virological response was defined as less than a 2 log-unit decline in the serum level of HCV RNA from the pretreatment baseline value within the first 12 weeks and detectable viremia 24 weeks after treatment. Virological response (VR) was defined as attaining SVR or transient virological response (TVR) in this study; SVR was defined as undetectable HCV RNA in serum 6 months after treatment, whereas TVR was defined as a reappearance of HCV RNA in serum after the treatment was discontinued for a patient who had undetectable HCV RNA during the therapy or on completion of the therapy. At the time of enrollment, written informed consent was obtained for the collection and storage of serum and peripheral blood. This study was conducted in accordance with provisions of the Declaration of Helsinki.

### Clinical and laboratory data

The sex, age, hemoglobin (Hb) and platelet counts were matched between study groups. Other parameters determined were as follows: alkaline phosphatase (ALP), alanine transaminase (ALT), total cholesterol, fasting blood sugar (FBS), low-density lipoprotein (LDL) cholesterol,  $\gamma$ -glutamyl transpeptidase ( $\gamma$ -GTP),  $\alpha$ -fetoprotein (AFP), HCV RNA level and the rs8099917 polymorphism near *IL28B*.

### DNA extraction

Genomic DNA was extracted from the buffy coat fraction of patients' whole blood using a GENOMIX kit (Talent SRL; Trieste, Italy).

### *IL28B* genotyping

We have reported that the rs8099917 polymorphism is the best predictor for the response of Japanese CHC patients to PEG IFN/RBV therapy than other SNP near *IL28B*.<sup>14</sup> Therefore, the rs8099917 polymorphism was genotyped using the InvaderPlus assay (Third Wave Japan, Tokyo, Japan), which combines polymerase

chain reaction (PCR) and the invader reaction.<sup>15,16</sup> The InvaderPlus assay was performed using the LightCycler LC480 (Roche Applied Science, Mannheim, Germany).

### Detection of amino acid substitutions in core and NS5A regions of HCV-1b

In the present study, substitutions of amino acid residues 70 (s-aa 70) and 91 (s-aa 91), and the presence of the IFN sensitivity-determining region (ISDR) were determined by direct nucleotide sequencing. HCV RNA was extracted from serum samples at the start of patients' therapy and reverse transcribed with a random primer and SuperScript III reverse transcriptase (Life Technologies, Carlsbad, CA, USA). Nucleic acids were amplified by PCR as described.<sup>17</sup>

### Statistical analysis

Quantitative variables were expressed as the mean  $\pm$  standard error (SE) unless otherwise specified. Categorical variables were compared using a  $\chi^2$ -test or Fisher's exact test, as appropriate, and continuous variables were compared using the Mann-Whitney *U*-test.  $P < 0.05$  was considered statistically significant. Multivariate analysis was performed using a stepwise logistic regression model. We performed statistical analyses using STATA ver. 11.0 (StataCorp, College Station, TX, USA).

## RESULTS

### Patient characteristics and *IL28B* genotype in a matched case-control study

TABLE 1 SHOWS PATIENT characteristics according to *IL28B* genotype. In a matched case-control study, sex, age, Hb levels and platelet counts were matched between 130 patients with rs8099917 TT genotype and 96 patients with rs8099917 TG or GG genotype. Lower  $\gamma$ -GTP ( $P = 0.013$ ) and higher LDL cholesterol levels ( $P < 0.001$ ) were significantly associated with the TT genotype of rs8099917. The percentages of wild type of s-aa 70 and s-aa 91 of patients with the rs8099917 TT genotype were significantly higher than those of patients with rs8099917 TG or GG genotype (s-aa 70: TT vs TG + GG, 68% vs 37% [ $P < 0.001$ ]; s-aa 91: TT vs TG + GG, 68% vs 51% [ $P = 0.017$ ]).

### Factors associated with NVR in total patients

Table 2 shows the factors associated with NVR by univariate and multivariate analyses. Univariate analysis showed that older age ( $P = 0.002$ ), lower platelet counts ( $P = 0.01$ ), higher  $\gamma$ -GTP ( $P = 0.013$ ), lower total cholesterol ( $P = 0.017$ ), lower LDL cholesterol ( $P < 0.001$ ) levels and higher AFP levels ( $P = 0.019$ ) were significantly associated with NVR. The percentage of TG or GG genotype of rs8099917 of patients with NVR was

**Table 1** Univariate analysis of *IL28B* TT and TG + GG genotypes

Variable	TT genotype ( <i>n</i> = 130)	TG + GG genotype ( <i>n</i> = 96)	<i>P</i> -value
Sex (% male)	61 (47)	46 (48)	Matched
Age (years), mean (SE)	57.2 (0.8)	57.5 (0.9)	Matched
Hemoglobin (g/dL), mean (SE)	14.3 (0.3)	13.9 (0.2)	Matched
Platelet count (/ $\mu$ L), mean (SE)	16.2 (0.5)	16.0 (0.5)	Matched
ALT (IU/L), mean (SE)	79.4 (5.4)	80.5 (7.8)	0.281
ALP (IU/L), mean (SE)	273.8 (11.7)	283.9 (11.8)	0.313
$\gamma$ -GTP (IU/L), mean (SE)	63.4 (6.0)	76.0 (6.4)	0.013
Total cholesterol (mg/dL), mean (SE)	177.5 (3.3)	172.3 (3.2)	0.345
LDL cholesterol (mg/dL), mean (SE)	99.0 (2.6)	83.5 (2.8)	<0.001
Fasting blood sugar (mg/dL), mean (SE)	114.1 (4.1)	104.4 (1.9)	0.97
AFP (ng/dL), mean (SE)	9.8 (1.1)	11.5 (1.6)	0.190
HCV RNA (log IU), mean (SE)	6.2 (0.1)	6.1 (0.1)	0.186
s-aa 70 wild type (%)	70/103 (68)	30/81 (37)	<0.001
s-aa 91 wild type (%)	70/103 (68)	41/81 (51)	0.017
ISDR mutation 0–1 point (%)	82/100 (82)	70/81 (86)	0.42

AFP,  $\alpha$ -fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase;  $\gamma$ -GTP,  $\gamma$ -glutamyl transpeptidase; HCV, hepatitis C virus; ISDR, interferon sensitivity-determining region; LDL, low-density lipoprotein; SE, standard error.

**Table 2** Univariate and multivariate analyses of patients with chronic hepatitis C treated with PEG IFN/RBV with respect to VR and NVR

Variable	Univariate analysis			Multivariate analysis	
	VR ( <i>n</i> = 128)	NVR ( <i>n</i> = 98)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value
Sex (% male)	65 (51)	42 (43)	0.237		
Age (years), mean (SE)	55.6 (0.8)	59.6 (0.9)	0.002	1.075 (1.012–1.143)	0.02
rs8099917 (TG or GG genotype) (%)	23/128 (18)	73/98 (74)	<0.001	25.460 (7.436–87.169)	<0.001
Hemoglobin (g/dL), mean (SE)	14.4 (0.3)	13.7 (0.2)	0.053		
Platelet count ( $\mu$ L), mean (SE)	16.9 (0.5)	15.0 (0.5)	0.01		
ALT (IU/L), mean (SE)	83.9 (6.4)	74.5 (6.2)	0.116		
ALP (IU/L), mean (SE)	274.1 (12.3)	282.9 (11.2)	0.169		
$\gamma$ -GTP (IU/L), mean (SE)	65.9 (6.4)	72.6 (5.6)	0.013		
Total cholesterol (mg/dL), mean (SE)	180.3 (3.1)	168.4 (3.5)	0.017		
LDL cholesterol (mg/dL), mean (SE)	100.5 (2.7)	83.5 (2.8)	<0.001	0.978 (0.956–0.999)	0.046
Fasting blood sugar (mg/dL), mean (SE)	106.6 (2.9)	114.8 (4.4)	0.058		
AFP (ng/dL), mean (SE)	9.6 (1.1)	12.0 (1.6)	0.021		
HCV RNA (Log IU), mean (SE)	6.2 (0.1)	6.2 (0.1)	0.876		
s-aa 70 wild type (%)	67/102 (66)	33/82 (54)	0.001		
s-aa 91 wild type (%)	67/102 (66)	44/82 (54)	0.097		
ISDR mutation 0–1 point (%)	79/96 (82)	73/85 (86)	0.511		

AFP,  $\alpha$ -fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CI, confidence interval;  $\gamma$ -GTP,  $\gamma$ -glutamyl transpeptidase; HCV, hepatitis C virus; ISDR, interferon sensitivity-determining region; LDL, low-density lipoprotein; NVR, non-virological response; OR, odds ratio; PEG IFN, peginterferon; SE, standard error; RBV, ribavirin; VR, virological response.


significantly higher than that of patients with VR (VR vs NVR: 23/128 [18%] vs 73/98 [74%],  $P < 0.001$ ). The percentage of wild-type s-aa 70 in patients with NVR was significantly lower than that in patients with VR [VR vs NVR: 67/102 [66%] vs 33/82 [54%],  $P = 0.001$ ]. Multivariate analysis showed that older age (odds ratio [OR] = 1.075; 95% confidence interval [CI] = 1.012–1.14;  $P = 0.02$ ), TG or GG genotype of rs8099917 (OR = 25.460; 95% CI = 7.436–87.169;  $P < 0.001$ ) and lower LDL cholesterol levels (OR = 0.978; 95% CI = 0.956–0.999;  $P = 0.046$ ) were independently associated with NVR.

### VR to treatment depending on *IL28B* genotype

In the patients with the rs8099917 TT genotype, the rates of SVR, TVR and NVR were 62%, 19% and 19%, respectively. Therefore, 19% patients were NVR, even though rs8099917 represents the TT genotype (predicted as VR). In contrast, in the patients with rs8099917 TG or GG, the rates of SVR, TVR and NVR were 14%, 10% and 76%, respectively. Therefore, 24% patients were VR, even though rs8099917 was TG or GG genotype (predicted as NVR) (Fig. 1).

### Factors associated with NVR in patients with the rs8099917 TT genotype

Table 3 shows the factors associated with NVR in patients with the rs8099917 TT genotype (predicted as VR) by univariate and multivariate analyses. Univariate analysis showed that female sex ( $P = 0.003$ ), older age



**Figure 1** Virological responses to pegylated interferon and ribavirin therapy were shown in patients with rs8099917 TT (a) and TG + GG (b). NVR, non-virological response; SVR, sustained virological response; TVR, transient virological response.

**Table 3** Variables associated with NVR by univariate and multivariate analyses in patients with rs8099917 TT genotype

Variable	Univariate analysis			Multivariate analysis	
	VR ( <i>n</i> = 105)	NVR ( <i>n</i> = 25)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value
Sex (% male)	56 (53)	5 (20)	0.003		
Age (years), mean (SE)	56.1 (0.8)	61.7 (1.6)	0.001	1.142 (1.026–1.271)	0.015
Hemoglobin (g/dL), mean (SE)	14.6 (0.4)	13.1 (0.3)	0.005		
Platelet count (/μL), mean (SE)	16.7 (0.6)	13.8 (1.0)	0.019		
ALT (IU/L), mean (SE)	83.6 (6.3)	61.0 (7.9)	0.053		
ALP (IU/L), mean (SE)	270.6 (13.6)	285.9 (22.3)	0.206		
γ-GTP (IU/L), mean (SE)	66.9 (7.1)	49.2 (7.4)	0.473		
Total cholesterol (mg/dL), mean (SE)	180.2 (3.6)	165.0 (7.6)	0.072		
LDL cholesterol (mg/dL), mean (SE)	101.2 (2.9)	88.5 (5.2)	0.067		
Fasting blood sugar (mg/dL), mean (SE)	108.4 (3.5)	140.0 (15.5)	0.127		
AFP (ng/dL), mean (SE)	9.4 (1.2)	12.2 (3.6)	0.245		
HCV RNA (log IU), mean (SE)	6.2 (0.1)	6.2 (0.1)	0.948		
s-aa 70 wild type (%)	57/83 (66)	13/20 (75)	0.752		
s-aa 91 wild type (%)	55/83 (66)	15/20 (75)	0.452		
ISDR mutation 0–1 point (%)	64/79 (81)	18/21 (86)	0.618		

AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CI, confidence interval; γ-GTP, γ-glutamyl transpeptidase; HCV, hepatitis C virus; ISDR, interferon sensitivity-determining region; LDL, low-density lipoprotein; NVR, non-virological response; OR, odds ratio; SE, standard error; VR, virological response.

(*P* = 0.001), lower Hb levels (*P* = 0.005) and lower platelet counts (*P* = 0.019) were significantly associated with NVR in patients with the rs8099917 TT genotype. Multivariate analysis showed that only older age was independently associated with NVR in patients with the rs8099917 TT genotype (predicted as VR) (OR = 1.142; 95% CI = 1.026–1.27; *P* = 0.015).

#### Factors associated with VR in patients with the rs8099917 TG or GG genotypes

Table 4 shows the factors associated with VR in patients with the rs8099917 TG or GG genotypes (predicted as NVR) by univariate and multivariate analyses. Younger age (*P* = 0.005), lower γ-GTP (*P* = 0.009) and higher LDL cholesterol levels (*P* = 0.032) were significantly associated with VR by univariate analysis. Multivariate analysis showed that only younger age was independently associated with VR in patients with the rs8099917 TG or GG genotype (predicted as NVR) (OR = 0.926; 95% CI = 0.867–0.990; *P* = 0.023).

#### Rate of VR depending on the rs8099917 genotype of each age group

We divided patients into four age groups and compared VR rates by the differences in rs8099917 genotype for each group. The rate of VR decreased gradually in the older age groups independent of genotype. In the less than 49 years age group, the rate of VR in patients with

the rs8099917 TT genotype was significantly higher than that in patients with the rs8099917 TG + GG genotypes (*P* = 0.0002). Further, in the 50–59 and 60–69 years age groups, the rates of VR in patients with the rs8099917 TT genotype were significantly higher than those in patients with the rs8099917 TG + GG genotypes (*P* < 0.0001, respectively). In the group that included subjects aged older than 69 years, only 50% of patients achieved VR even in those with the rs8099917 TT genotype (predicted as VR). In contrast, 47.6% of patients achieved VR, including those with the rs8099917 TG or GG genotypes (predicted as NVR) in the less than 49 years group (Fig. 2).

## DISCUSSION

SINGLE NUCLEOTIDE POLYMORPHISM array analysis employing GWAS technology conducted by our laboratory and others revealed the relationships between SNP associated with the *IL28B* locus or present within the coding sequences for IFN-λ3, or the response to PEG IFN/RBV therapy for CHC.<sup>7–9</sup> Subsequent studies have confirmed that the response to PEG IFN/RBV therapy correlates with the SNP associated with *IL28B*<sup>18,19</sup> and indicates their value for predicting the response to PEG IFN/RBV therapy. Unfortunately, these predictions do not hold for some patients. In an attempt to understand the reasons for this, in the present study,


**Table 4** Variables associated with VR by univariate and multivariate analyses in patients with rs8099917 TG or GG genotypes

Variable	Univariate analysis			Multivariate analysis	
	VR (n = 23)	NVR (n = 73)	P-value	OR (95% CI)	P-value
Sex (% male)	9 (40%)	37 (51%)	0.333		
Age (years), mean (SE)	53.2 (1.7)	58.8 (1.1)	0.005	0.926 (0.867–0.990)	0.023
Hemoglobin (g/dL), mean (SE)	13.6 (0.3)	13.9 (0.2)	0.44		
Platelet count (/μL), mean (SE)	17.6 (1.1)	15.5 (0.6)	0.059		
ALT (IU/L), mean (SE)	85.5 (21.6)	78.9 (7.8)	0.767		
ALP (IU/L), mean (SE)	291.9 (28.6)	281.8 (13.0)	0.921		
γ-GTP (IU/L), mean (SE)	62.2 (15.1)	80.4 (6.9)	0.009		
Total cholesterol (mg/dL), mean (SE)	180.5 (6.2)	169.5 (3.7)	0.17		
LDL cholesterol (mg/dL), mean (SE)	97.6 (6.9)	81.9 (3.6)	0.032		
Fasting blood sugar (mg/dL), mean (SE)	98.1 (2.8)	106.3 (2.3)	0.084		
AFP (ng/dL), mean (SE)	10.3 (3.4)	11.9 (1.8)	0.123		
HCV RNA (log IU), mean (SE)	5.9 (0.1)	6.2 (0.1)	0.087		
s-aa 70 wild type (%)	10/19 (53)	20/62 (32)	0.108		
s-aa 91 wild type (%)	12/19 (63)	29/62 (47)	0.211		
ISDR mutation 0–1 point (%)	15/17 (88)	55/64 (86)	0.806		

AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CI, confidence interval; γ-GTP, γ-glutamyl transpeptidase; HCV, hepatitis C virus; ISDR, interferon sensitivity-determining region; LDL, low-density lipoprotein; NVR, non-virological response; OR, odds ratio; SE, standard error; VR, virological response.

we recruited a new set of patients for further analysis. Here, we confirmed that *IL28B* polymorphism was the most significant predictive factor for NVR with respect to PEG IFN/RBV treatment. Moreover, 19% of patients exhibiting the rs8099917 TT genotype were NVR,

although they were predicted as VR. Twenty-four percent of patients with the rs8099917 TG or GG genotypes were VR, although they were predicted as NVR. We were able to determine by multivariate analysis that age was the most likely factor responsible for the discordance



**Figure 2** Virological responses (VR) to pegylated interferon and ribavirin therapy were compared between the patients with rs8099917 TT and TG + GG in each generation group. (■) Total patients, (□) TT genotype (rs8099917), (▒) TG + GG genotype (rs8099917).

between *IL28B* genotype and patients' response to viral infection.

How does age influence the VR to PEG IFN/RBV therapy? First, the lower rate of VR to PEG IFN/RBV therapy in patients with CHC was attributed to lower compliance with the IFN or RBV dose.<sup>20,21</sup> Because lower compliance with PEG IFN or RBV therapy was expected to be associated with a lower rate of VR in older patients, we recruited patients who were administered over 80% of the prescribed dose of IFN/RBV. Therefore, lower compliance can be discounted as a reason for reduced response. Second, a more advanced stage of fibrosis might have been present in the older group. Platelet counts in patients with NVR were significantly lower than those in patients with VR, and lower platelet counts may be associated with advanced fibrosis.<sup>22</sup> Moreover, advanced fibrosis is associated with lower rates of SVR to IFN-based therapy.<sup>23</sup> Third, epigenetic factors such as DNA methylation induced by aging may be involved in the reduced efficacy of PEG IFN/RBV treatment in older patients. DNA methylation near gene promoters is known to turn off transcription or reduce it considerably,<sup>24</sup> and advanced age is strongly associated with the increased DNA methylation.<sup>25</sup> Therefore, DNA methylation may be increased near or in the *IL28B* promoter as a function of age resulting in suppression of *IL28B* transcription.

Lower LDL cholesterol levels were significantly associated with NVR in patients with CHC. Moreover, LDL cholesterol levels in patients with the rs8099917 TT genotype were significantly higher than those in patients with the TG + GG genotypes. The association between LDL cholesterol and *IL28B* polymorphism as well as the VR to PEG IFN/RBV has been reported.<sup>26</sup> Higher pre-treatment levels of LDL cholesterol have been shown to predict increased response to standard PEG IFN/RBV treatment for patients with CHC.<sup>27,28</sup> Although the mechanisms responsible for the association between LDL cholesterol levels and the VR to PEG IFN/RBV are unknown, the *IL28B*-rs8099917 TT responder genotype, which may correlate with an increased likelihood of treatment response and higher LDL cholesterol levels, is associated with either lower IFN- $\lambda$ 3 activity or reduced expression of genes regulated by IFN-mediated signaling pathways.

In conclusion, our studies provide compelling evidence that patient age is most likely responsible for incorrect predictions of VR to PEG IFN/RBV therapy in Japanese CHC patients based on *IL28B* genotypes. Our findings indicated that patients should be treated as soon as they are diagnosed. It will be important to

investigate the role of the epigenetic factors associated with *IL28B* expression to develop more effective PEG IFN/RBV-based therapies for patients with CHC.

## ACKNOWLEDGMENT

THIS STUDY WAS supported by grants (21-112 and 21-113) from the National Center for Global Health and Medicine in Japan.

## REFERENCES

- 1 Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. *J Clin Pharmacol* 2004; 44: 20–9.
- 2 Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. *Hepatology* 2007; 45: 806–16.
- 3 Fried MW, Shiffman ML, Reddy KR *et al.* Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975–82.
- 4 Manns MP, McHutchison JG, Gordon SC *et al.* Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958–65.
- 5 Hadziyannis SJ, Sette H, Jr, Morgan TR *et al.* Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140: 346–55.
- 6 Bruno S, Camma C, Di Marco V *et al.* Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. *J Hepatol* 2004; 41: 474–81.
- 7 Tanaka Y, Nishida N, Sugiyama M *et al.* Genome-wide association of *IL28B* with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009; 41: 1105–9.
- 8 Ge D, Fellay J, Thompson AJ *et al.* Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature* 2009; 461: 399–401.
- 9 Suppiah V, Moldovan M, Ahlenstiel G *et al.* *IL28B* is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009; 41: 1100–4.
- 10 Watanabe S, Enomoto N, Koike K *et al.* Cancer preventive effect of pegylated interferon alpha-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. *Hepatol Res* 2011; 41: 955–64.
- 11 Kurosaki M, Tanaka Y, Nishida N *et al.* Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in *IL28B* and viral factors. *J Hepatol* 2011; 54: 439–48.
- 12 Kurosaki M, Sakamoto N, Iwasaki M *et al.* Pretreatment prediction of response to peginterferon plus ribavirin